Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP655349.RAqKF8KVkWYwnuFVZtNSqSpD5s9_uFcO9G0tlblsehmb4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP655349.RAqKF8KVkWYwnuFVZtNSqSpD5s9_uFcO9G0tlblsehmb4130_assertion type Assertion NP655349.RAqKF8KVkWYwnuFVZtNSqSpD5s9_uFcO9G0tlblsehmb4130_head.
- NP655349.RAqKF8KVkWYwnuFVZtNSqSpD5s9_uFcO9G0tlblsehmb4130_assertion description "[The positive clinical experience seen in MDS to date coupled with the persistent challenges faced in the treatment of other hematologic malignancies has served as the impetus for further exploration of the therapeutic value of DNMT inhibitors beyond MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP655349.RAqKF8KVkWYwnuFVZtNSqSpD5s9_uFcO9G0tlblsehmb4130_provenance.
- NP655349.RAqKF8KVkWYwnuFVZtNSqSpD5s9_uFcO9G0tlblsehmb4130_assertion evidence source_evidence_literature NP655349.RAqKF8KVkWYwnuFVZtNSqSpD5s9_uFcO9G0tlblsehmb4130_provenance.
- NP655349.RAqKF8KVkWYwnuFVZtNSqSpD5s9_uFcO9G0tlblsehmb4130_assertion SIO_000772 16341239 NP655349.RAqKF8KVkWYwnuFVZtNSqSpD5s9_uFcO9G0tlblsehmb4130_provenance.
- NP655349.RAqKF8KVkWYwnuFVZtNSqSpD5s9_uFcO9G0tlblsehmb4130_assertion wasDerivedFrom befree-20140225 NP655349.RAqKF8KVkWYwnuFVZtNSqSpD5s9_uFcO9G0tlblsehmb4130_provenance.
- NP655349.RAqKF8KVkWYwnuFVZtNSqSpD5s9_uFcO9G0tlblsehmb4130_assertion wasGeneratedBy ECO_0000203 NP655349.RAqKF8KVkWYwnuFVZtNSqSpD5s9_uFcO9G0tlblsehmb4130_provenance.